Key Takeaways
- Iran's IRGC launched a drone attack on a US military base in Kuwait and struck a cargo vessel near the Strait of Hormuz, sharply escalating regional tensions despite ongoing diplomatic efforts.
- Merck & Co. (MRK) beat Q2 revenue and adjusted EPS expectations but slashed its full-year EPS guidance by nearly 50% due to significant charges from the Terns Pharmaceuticals and Cidara deals.
- Kimberly-Clark (KMB) reported an earnings beat with adjusted EPS of $2.12, but shares faced pressure as the company lowered its organic sales growth outlook due to a misinformation campaign impacting diaper sales in China.
- Qatar confirmed a draft agreement is circulating between the US and Iran aimed at a short-term de-escalation, though both sides have yet to commit to direct negotiations.
- Leaked documents from Elbit Systems (ELST) revealed secret negotiations for billions of dollars in advanced drone sales to the UAE, highlighting deepening defense ties following the Abraham Accords.
Geopolitical Volatility: Attacks in Kuwait and Hormuz
Regional stability was shaken early Tuesday as Iran’s Islamic Revolutionary Guard Corps (IRGC) reportedly targeted a US military base in Kuwait with at least three drones. The attack coincided with reports from the United Kingdom Maritime Trade Operations (UKMTO) that a merchant vessel was struck by a projectile approximately 20 nautical miles northeast of Al Khasab, Oman, near the strategic Strait of Hormuz.
These hostilities come at a critical juncture for the White House, as President Donald Trump recently characterized diplomatic talks as a "last chance" for Tehran. While Qatar and Oman continue to mediate, with Qatari officials confirming that "language has been drafted" for a possible deal, the resumption of kinetic strikes threatens to collapse the fragile 60-day ceasefire framework intended to keep the Strait of Hormuz open.
Pharmaceutical and Consumer Goods Earnings
Merck & Co. (MRK) delivered a complex Q2 report, posting sales of $16.61 billion, which exceeded the $16.35 billion analyst consensus. Growth was fueled by its oncology blockbuster Keytruda, which brought in $8.37 billion, and a strong performance in its Animal Health division. However, the company drastically lowered its FY2026 adjusted EPS guidance to $2.66–$2.76 from a previous range of $5.04–$5.16, accounting for roughly $14.7 billion in combined charges related to the acquisitions of Terns Pharmaceuticals and Cidara Therapeutics.
Kimberly-Clark (KMB) also reported its second-quarter results, beating adjusted EPS estimates of $2.00 with a realized $2.12. Despite the earnings strength, net sales of $4.19 billion slightly missed the $4.23 billion target. Management warned that 2026 organic sales growth is now expected to track approximately 100 basis points below average category growth, primarily due to "discrete disruptions" in the China market stemming from social media misinformation regarding its diaper brands.
Defense and Energy Market Implications
The defense sector saw renewed scrutiny following a massive data leak from Israeli manufacturer Elbit Systems (ELST). Stolen documents allegedly show the UAE requested an "urgent" supply of Hermes-900 strategic drones and SkyStriker loitering munitions worth upwards of $1.3 billion to counter regional threats. This leak underscores the rapid expansion of Israeli-Emirati military cooperation, which has reportedly reached $2.3 billion in total strategic equipment sales as of 2024.
In the energy markets, the threat of a US fuel export ban looms as a potential "emergency option" for the administration to curb rising domestic gasoline prices ahead of the midterm elections. While crude benchmarks have climbed on the back of the Kuwait base attack and Hormuz uncertainty, analysts warn that restricting exports could lead to domestic refinery imbalances, potentially exacerbating long-term supply issues despite short-term price relief at the pump.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.